PDS Biotechnology (PDSB) Competitors $1.17 -0.07 (-5.65%) Closing price 04:00 PM EasternExtended Trading$1.17 0.00 (-0.34%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB vs. MNPR, CRGX, PRQR, ACIU, AVTE, CTNM, VYGR, HRTX, LYEL, and ACRSShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Monopar Therapeutics (MNPR), CARGO Therapeutics (CRGX), ProQR Therapeutics (PRQR), AC Immune (ACIU), Aerovate Therapeutics (AVTE), Contineum Therapeutics (CTNM), Voyager Therapeutics (VYGR), Heron Therapeutics (HRTX), Lyell Immunopharma (LYEL), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. Its Competitors Monopar Therapeutics CARGO Therapeutics ProQR Therapeutics AC Immune Aerovate Therapeutics Contineum Therapeutics Voyager Therapeutics Heron Therapeutics Lyell Immunopharma Aclaris Therapeutics Monopar Therapeutics (NASDAQ:MNPR) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership. Which has more risk & volatility, MNPR or PDSB? Monopar Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Is MNPR or PDSB more profitable? Monopar Therapeutics' return on equity of -41.76% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -41.76% -39.49% PDS Biotechnology N/A -184.56%-79.00% Which has higher earnings and valuation, MNPR or PDSB? Monopar Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.33-10.06PDS BiotechnologyN/AN/A-$37.61M-$0.92-1.27 Does the media favor MNPR or PDSB? In the previous week, Monopar Therapeutics had 5 more articles in the media than PDS Biotechnology. MarketBeat recorded 18 mentions for Monopar Therapeutics and 13 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.69 beat Monopar Therapeutics' score of 0.57 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MNPR or PDSB? Monopar Therapeutics presently has a consensus target price of $60.00, suggesting a potential upside of 79.05%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 669.23%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do institutionals and insiders hold more shares of MNPR or PDSB? 1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 20.5% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryMonopar Therapeutics and PDS Biotechnology tied by winning 7 of the 14 factors compared between the two stocks. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.56M$3.07B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-1.2720.4830.7825.12Price / SalesN/A355.18456.64116.46Price / CashN/A41.5625.2228.45Price / Book2.299.549.375.95Net Income-$37.61M-$54.74M$3.26B$265.46M7 Day Performance-4.88%2.39%1.88%0.96%1 Month Performance1.74%4.60%3.73%2.47%1 Year Performance-66.76%9.17%28.93%20.24% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology2.0991 of 5 stars$1.17-5.6%$9.00+669.2%-61.8%$54.56MN/A-1.2720Earnings ReportMNPRMonopar Therapeutics2.8632 of 5 stars$34.26-4.1%$60.00+75.1%+1,370.4%$220.33MN/A-10.2910Earnings ReportAnalyst RevisionCRGXCARGO Therapeutics2.3467 of 5 stars$4.47-1.5%$15.40+244.5%-73.0%$219.57MN/A-0.96116High Trading VolumePRQRProQR Therapeutics2.627 of 5 stars$2.12+3.4%$8.00+277.4%-3.6%$215.69M$20.46M-4.61180News CoverageACIUAC Immune2.0123 of 5 stars$2.15+0.9%$12.00+458.1%-36.2%$213.87M$31.02M-3.71140Positive NewsAVTEAerovate TherapeuticsN/A$7.36+8.7%N/A-88.2%$213.33MN/A-2.4620High Trading VolumeCTNMContineum Therapeutics3.3033 of 5 stars$8.10+9.8%$22.75+180.9%-52.7%$206.95M$50M-3.6831News CoverageAnalyst ForecastShort Interest ↓VYGRVoyager Therapeutics3.593 of 5 stars$3.84+2.9%$13.25+245.0%-40.6%$206.90M$80M-2.08100HRTXHeron Therapeutics4.2479 of 5 stars$1.30-2.3%$4.50+246.2%-32.6%$203.88M$144.29M-65.00300Positive NewsLYELLyell Immunopharma3.3016 of 5 stars$10.89+2.9%$15.00+37.7%-55.4%$203.26M$60K-0.45270Earnings ReportAnalyst DowngradeACRSAclaris Therapeutics2.7508 of 5 stars$1.85-1.1%$8.71+371.0%+55.5%$202.58M$18.72M-1.35100 Related Companies and Tools Related Companies MNPR Competitors CRGX Competitors PRQR Competitors ACIU Competitors AVTE Competitors CTNM Competitors VYGR Competitors HRTX Competitors LYEL Competitors ACRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDSB) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access